BC Week In Review | Oct 13, 2017
Clinical News

Medix Products begins Phase III of obesity candidate

Medix Products S.A. de C.V. (Mexico City, Mexico) began a Phase III trial of tesofensine (NS2330) to treat obesity. The double-blind, placebo-controlled, Mexican trial will evaluate once-daily 0.25 and 0.5 mg doses of tesofensine for...
BC Extra | Sep 19, 2016
Clinical News

Teva HD candidate pridopidine heading for Phase III

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) hopes to begin a Phase III program next year of pridopidine to treat Huntington's disease after seeing possible evidence of a disease-modifying effect in the exploratory Phase II PRIDE-HD study....
BioCentury | Sep 28, 2015
Regulation

Serving nerves

Testimony at the first of FDA's patient-focused drug development meetings last week revealed that several programs in industry's pipeline for Huntington's disease are aligned with patient and caregiver desires for drugs that could halt progression...
BioCentury | Apr 6, 2015
Strategy

Teva says I deu

The latest deal by Teva Pharmaceutical Industries Ltd. suggests the company has not changed course under new leadership, at least when it comes to building its CNS pipeline via business development. Last week, Teva said...
BC Week In Review | Nov 24, 2014
Company News

NeuroSearch, Saniona deal

NeuroSearch transferred to Saniona rights to NS2359 and tesofensine (NS2330). Saniona will assume the cost of maintaining patent rights to the compounds. NeuroSearch is eligible for up to 20% of any milestones and royalties that...
BC Week In Review | Oct 20, 2014
Company News

NeuroSearch neurology news

NeuroSearch appealed to the Eastern High Court of Denmark an August ruling from the City Court of Copenhagen ordering the company to pay a fine of DKK5 million ($851,000) for share price manipulation in violation...
BC Week In Review | Sep 29, 2014
Company News

Saniona, NeuroSearch, J&J deal

Saniona and Johnson & Johnson's Janssen Pharmaceutica N.V. subsidiary extended by 12 months to August 2015 a 2009 deal to discover and develop therapeutics for CNS diseases. The deal was originally between NeuroSearch and Janssen,...
BC Week In Review | May 5, 2014
Clinical News

Pridopidine: Phase II started

Teva began the double-blind, placebo-controlled, international Phase II PRIDE-HD trial to evaluate 45, 67.5, 90 and 112.5 mg oral pridopidine twice daily for 26 weeks in about 400 patients ages >=21 years with an onset...
BC Extra | Mar 20, 2014
Financial News

Saniona raises $2.7 million in Swedish IPO

Saniona AB (AktieTorget:SANION) raised SEK17 million ($2.7 million) in an IPO in Sweden through the sale of 3.4 million shares at SEK5. The price values the company at SEK69.4 million ($10.8 million). Saniona (formerly Aniona...
BC Week In Review | Nov 25, 2013
Company News

NeuroSearch board of directors update

NeuroSearch A/S (CSE:NEUR), Ballerup, Denmark   Business: Neurology   Appointed: Christian Lundgren, a director, as provisional chairman, effective Dec. 1; he succeeds Allan Andersen, who will transition to CEO; Andersen, succeeds Rene Schneider, who is...
Items per page:
1 - 10 of 387
BC Week In Review | Oct 13, 2017
Clinical News

Medix Products begins Phase III of obesity candidate

Medix Products S.A. de C.V. (Mexico City, Mexico) began a Phase III trial of tesofensine (NS2330) to treat obesity. The double-blind, placebo-controlled, Mexican trial will evaluate once-daily 0.25 and 0.5 mg doses of tesofensine for...
BC Extra | Sep 19, 2016
Clinical News

Teva HD candidate pridopidine heading for Phase III

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) hopes to begin a Phase III program next year of pridopidine to treat Huntington's disease after seeing possible evidence of a disease-modifying effect in the exploratory Phase II PRIDE-HD study....
BioCentury | Sep 28, 2015
Regulation

Serving nerves

Testimony at the first of FDA's patient-focused drug development meetings last week revealed that several programs in industry's pipeline for Huntington's disease are aligned with patient and caregiver desires for drugs that could halt progression...
BioCentury | Apr 6, 2015
Strategy

Teva says I deu

The latest deal by Teva Pharmaceutical Industries Ltd. suggests the company has not changed course under new leadership, at least when it comes to building its CNS pipeline via business development. Last week, Teva said...
BC Week In Review | Nov 24, 2014
Company News

NeuroSearch, Saniona deal

NeuroSearch transferred to Saniona rights to NS2359 and tesofensine (NS2330). Saniona will assume the cost of maintaining patent rights to the compounds. NeuroSearch is eligible for up to 20% of any milestones and royalties that...
BC Week In Review | Oct 20, 2014
Company News

NeuroSearch neurology news

NeuroSearch appealed to the Eastern High Court of Denmark an August ruling from the City Court of Copenhagen ordering the company to pay a fine of DKK5 million ($851,000) for share price manipulation in violation...
BC Week In Review | Sep 29, 2014
Company News

Saniona, NeuroSearch, J&J deal

Saniona and Johnson & Johnson's Janssen Pharmaceutica N.V. subsidiary extended by 12 months to August 2015 a 2009 deal to discover and develop therapeutics for CNS diseases. The deal was originally between NeuroSearch and Janssen,...
BC Week In Review | May 5, 2014
Clinical News

Pridopidine: Phase II started

Teva began the double-blind, placebo-controlled, international Phase II PRIDE-HD trial to evaluate 45, 67.5, 90 and 112.5 mg oral pridopidine twice daily for 26 weeks in about 400 patients ages >=21 years with an onset...
BC Extra | Mar 20, 2014
Financial News

Saniona raises $2.7 million in Swedish IPO

Saniona AB (AktieTorget:SANION) raised SEK17 million ($2.7 million) in an IPO in Sweden through the sale of 3.4 million shares at SEK5. The price values the company at SEK69.4 million ($10.8 million). Saniona (formerly Aniona...
BC Week In Review | Nov 25, 2013
Company News

NeuroSearch board of directors update

NeuroSearch A/S (CSE:NEUR), Ballerup, Denmark   Business: Neurology   Appointed: Christian Lundgren, a director, as provisional chairman, effective Dec. 1; he succeeds Allan Andersen, who will transition to CEO; Andersen, succeeds Rene Schneider, who is...
Items per page:
1 - 10 of 387